Notfallkontrazeption - ein update

Tho­mas Rabe, Chris­ti­an Alb­ring, Hans-Jo­a­chim Ah­rendt, Jo­han­nes Bit­zer, Chris­ti­an Ega­ter, Klaus Kö­nig, Alfred O. Mueck,  Gab­rie­le Mer­ki, Eli­sa­beth Merkle

 

  1. Gem­zell-Da­ni­els­son, K.; Ber­ger, C.; La­lit­kumar, P. G. L. Emer­gency con­tra­cep­ti­on – me­cha­nism of ac­tion. Con­tra­cep­ti­on 2013,87, 300?308.
  2. Rabe, T.; Alb­ring, C. et al. Not­fall­kon­tra­zep­ti­on – ein Up­da­te. Ge­mein­sa­men Stel­lung­nah­me der Deut­schen Ge­sell­schaft für Gy­nä­ko­lo­gi­sche End­okri­no­lo­gie und Fort­pflan­zungs­me­di­zin (DGGEF) e.V. und des Be­rufs­ver­bands der Frau­en­ärz­te (BVF) e.V. – Up­da­te vom 6.2.2013. Frauenarzt 2013, 54, 108–114.
  3. Nal­la­samy, S.; Kim, J.; Si­truk-Ware, R.; Bag­chi, M.; Bag­chi, I. Uli­pris­tal blocks ovu­la­ti­on by in­hi­bi­ting pro­geste­ro­ne re­cep­tor-de­pen­dent pa­thways intrin­sic to the ova­ry. Re­pro­duct. Sci. 2012, Re­prod Sci. 2013; 20(4): 371-381.
  4. Brache V., Cochon, L., Deniaud M., Croxatto H. B. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 2013, 88, 611-618.
  5. Trus­sel, J.; Rodríguez, G.; El­lert­son, C. New es­ti­ma­tes of the ef­fec­ti­veness of the Yuz­pe re­gi­men of emer­gency con­tra­cep­ti­on. Con­tra­cep­ti­on 1998, 57, 363–369.
  6. Gla­sier, A. F. Ca­me­ron, S. T.; Fine, P. M.; Lo­gan, S. J. S.; Ca­sa­le, W.; Van Horn, J.; So­gor, L.; Bli­the, D. L.; Scher­rer, B.; Ma­the, H.; Jas­part, A.; Ul­mann, A.; Gai­ner, E. Uli­pris­tal ace­ta­te ver­sus le­vo­nor­ge­strel for emer­gency con­tra­cep­ti­on: a ran­do­mi­sed non- in­fe­ri­o­ri­ty tri­al and meta-ana­ly­sis. The Lan­cet 2010, 375, 555-562.
  7.  Zhang, L.; Chen, J.; Wang, Y.; Ren, F.; Yu, W.; Cheng, L. Preg­nancy out­co­me af­ter le­vo­nor­ge­strel-only emer­gency con­tra­cep­ti­on fai­lu­re: a pro­spec­ti­ve co­hort study. Hum. Re­prod. 2009; 1; 1–7.
  8. Levy DP, Jager M, Kapp N, Abitbol JL. Uli­pris­tal ace­ta­te for emer­gency con­tra­cep­ti­on: post-mar­ke­ting ex­pe­ri­ence af­ter use by more than 1 mil­li­on wo­men. Con­tra­cep­ti­on 2014, 89, 431-433
  9. Gla­sier, A. F. Ca­me­ron, S. T.; Fine, P. M.; Lo­gan, S. J. S.; Ca­sa­le, W.; Van Horn, J.; So­gor, L.; Bli­the, D. L.; Scher­rer, B.; Ma­the, H.; Jas­part, A.; Ul­mann, A.; Gai­ner, E. Uli­pris­tal ace­ta­te ver­sus le­vo­nor­ge­strel for emer­gency con­tra­cep­ti­on: a ran­do­mi­sed non- in­fe­ri­o­ri­ty tri­al and meta-ana­ly­sis. The Lan­cet 2010, 375, 555-562.
  10. Gla­sier A, Cameron ST, Blithe D, Scher­rer B, Ma­the H, Levy D, Gainer E, Ulmann A. Can we iden­tify wo­men at risk of preg­nancy de­spi­te using emer­gency con­tra­cep­ti­on? Data from ran­do­mi­zed tri­als of uli­pris­tal ace­ta­te and le­vo­nor­ge­strel. Con­tra­cep­ti­on 2011, 84, 363-367
  11. Gla­sier A, Cameron ST, Blithe D, Scherrer B, Mathe H, Levy D, Gainer E, Ulmann A. Can we iden­tify wo­men at risk of preg­nancy de­spi­te using emer­gency con­tra­cep­ti­on? Data from ran­do­mi­zed tri­als of ulipristal acetate and levonorgestrel. Contraception 2011, 84, 363-367
  12.  www.ema.europa.eu/ema/index.jsp; 25.7.2014
  13. Task Force on Post­ovu­la­to­ry Me­thods of Fer­ti­li­ty Re­gu­la­ti­on. Rand­omi­sed con­trol­led tri­al of le­vo­nor­ge­strel ver­sus the Yuz­pe re­gi­men of com­bi­ned oral con­tra­cep­ti­ves for emer­gency con­tra­cep­ti­on. Lan­cet. 1998 Aug 8;352(9126):428-33.
  14. von Hert­zen H, Pi­ag­gio G, Van Look PF. Emer­gency con­tra­cep­ti­on with le­vo­nor­ge­strel or the Yuz­pe re­gi­men. Task Force on Post­ovu­la­to­ry Me­thods of Fer­ti­li­ty Re­gu­la­ti­on. Lan­cet. 1998 Dec 12;352(9144):1939.

 

 

 

 

 

 

 

 

 

 

Mikronährstoffe in den verschiedenen Lebensphasen der Frau (Teil 5) - Adoleszenz und frühes Erwachsenenalter

Janina Willers, Alexander Ströhle, Isabel Behrendt, Peyman Hadji, Andreas Hahn

 

  1. Deligeoroglou E, Tsimaris P (2010) Menstrual disturbances in puberty. Best Pract Res ClinObstetGynaecol 24(2): 157-71
  2. Rogol AD, Roemmich JN, Clark PA (2002) Growth at puberty. Journal of Adolescent Health 31: 192-200
  3. Koletzko B, Toschke AM, von Kries R (2004) Herausforderungen bei der Charakterisierung und der Verbesserung der Ernährungssituation im Kindes- und Jugendalter. Bundesgesundheitsbl 47: 227-234
  4. Mensink GB, Heseker H, Stahl A, Richter A, Vohmann C (2007) Die aktuelle Nährstoffversorgung von Kindern und Jugendlichen in Deutschland. ErnährungsUmschau 54: 636-646
  5. Dante et al
  6. Palmery A, Saraceno A, Vaiarelli A, Carlomagno G (2013) Oral contraceptives and changes in nutritional requirements. Eu Rev Med PharmacolSci 17: 1804-1813
  7. Wilson SMC, Bivins BN, Russell KA, Bailey LB (2011) Oral contraceptive use: impact on folate, vitamin B6, and vitamin B12 status. Nutrition Reviews 69(10): 572-583
  8. Schuchardt JP, Hahn A (2009) Eisen. DLR: 111-120
  9. Ekmekcioglu C (2000) Spurenelemente auf dem Weg ins 21. Jahrhundert – zunehmende Bedeutung von Eisen, Kupfer, Selen und Zink. J Ernährungsmed 2: 18-23
  10. Martius F (2009) Eisenmangel ohne Anämie – ein heisses Eisen? Schweiz Med Forum 9(15-16): 294-299
  11. Mettler S (2004) Ferrum – ein Mineralstoff im Sport. Schweizerische Zeitschrift für Sportmedizin und Sporttraumatologie 52(3): 105-114
  12. Harvey LJ, Armah CN, Dainty JR, Foxall RJ, Lewis DJ, Langford NJ, Fairwather-Tait SJ (2005) Impact of menstrual blood loss and diet on iron deficiency among women in the UK. British Journal of Nutrition 94: 557-564
  13. Hürlimann 2013
  14. Siemens HJ, Ludwig M (2012) Diagnostik des Eisenmangels. Frauenarzt 53: 1039-49
  15. Nielsen 2007
  16. Zimmermann MB, Hurrell RF (2007) Nutritional iron deficiency. Lancet 370: 511-520
  17. Milman N, Clausen J, Byg KE (1998) Iron status in 268 Danish women aged 18-30 years: influence of menstruation, contraceptive method, and iron supplementation. Ann Hematol 77(1-2): 13-9
  18. Di Santolo M, Stel G, Banfi G, Gonano F, Cauci S (2008) Anemia and iron status in young fertile non-professional female athlets. Eur J ApplPhysiol 102: 703-709
  19. Fogelholm M, Alopaeus K, Silvennoinen T, Teirila J (1993) Factors affecting iron status in non-pregnant women from urban south Finland. Eur J ClinNutr 47(8): 567-74
  20. Pynaert I, De Bacquer D, Matthys C, Delanghe J, Temmerman M, De Backer G, De Henauw S (2009) Determinants of ferritin and soluble transferrin receptors as iron status parameters in young adult women. Public Health Nutr 12(10): 1775-82
  21. Bilian X (2002) Intrauterine devices. Best Pract Res ClinObstetGynaecol 16(2): 155-68
  22. Galan P, Yoon HC, Preziosi P, Viteri F, Valeix P, Fieux B, Briançon S, Malvy D, Roussel AM, Favier A, Hercberg S (1998) Determining factors in the iron status of adult women in the SU.VI.MAX study. SUpplementation en VItaminesetMinérauxAntioXydants. Eur J ClinNutr  52(6): 383-8
  23. Casabellata G, Di Santolo M, Banfi G, Stel G, Gonano F, Cauci S (2007) Evaluation of iron deficiency in young women in relation to oral contraceptive use. Contraception 76(3): 200-7
  24. Vohr HW (Hrsg.) (2010) Toxikologie. Band 2: Toxikologie der Stoffe. WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
  25. Domke A, Großklaus R, Niemann B, Przyrembel H, Richter K, Schmidt E, Weißenborn A, Wörner B, Ziegenhagen R (Hrsg.) (2004) Verwendung von Mineralstoffen in Lebensmitteln – Toxikologische und ernährungsphysiologische Aspekte Teil II. BfR Wissenschaft, Berlin
  26. Geisser P, Mühlebach S (2010) Orale Eisensubstitution: Eisen(II)-Salze und Eisenpolymaltosekomplex. SZE 1: 20-23
  27. Hahn A, Schuchardt JP (2011) Mineralstoffe – Stoffwechsel, Funktionen und Bedarf. B. Behr’s Verlag GmbH & Co. KG, Hamburg
  28. Max Rubner Institut, Bundesforschungsinstitut für Ernährung und Lebensmittel, Karlsruhe (Hrsg.): Nationale Verzehrsstudie II Ergebnisteil 2: www.was-esse-ich.de/uploads /media/NVSII_ Abschlussbericht _Teil _2.pdf  (Zugriff: 26.06.2014)
  29. Hadji P, Klein S, Gothe H, Häussler B, Kless T, Schmidt T, Steinle T, Verheyen F, Linder R (2013) Epidemiologie der Osteoporose: Bone Evaluation Study. Deutsches Ärzteblatt 110 (4):52-57
  30. Stettin D, Ströhle A, Wolters M, Hahn A (2005) Ernährung und Osteoporose – Bedeutung von Calcium und Vitamin D. DAZ 145(15): 1-7
  31. Jackman LA, Millane SS, Martin BR, Wood OB, McCabe GP, Peacock M, Weaver CM. Calcium retention in relation to calcium intake and postmenarcheal age in adolescent females. Am J ClinNutr. 1997 Aug;66(2):327-333
  32. Yin J, Zhang Q, Liu A, Du W, Wang X, Hu X, Ma G (2010) Calcium supplementation for 2 years improves bone mineral accretion and lean body mass in Chinese adolescents. Asia Pac J ClinNutr 19(2):152-60
  33. Huncharek M, Muscat J, Kupelnick B (2008) Impact of dairy products and dietary calcium on bone-mineral content in children: results of a meta-analysis. Bone. 2008, 43(2):312-21
  34. Lambert HL, Eastell R, Karnik K, Russell JM, Barker ME (2008) Calcium supplementation and bone mineral accretion in adolescent girls: an 18-mo randomized controlled trial with 2-y follow-up. Am J ClinNutr 87(2):455-62
  35. Wiegratz I, Thaler CJ (2011) Hormonale Kontrazeption – was, wann, für wen? Dt. Ärzteblatt 108, 28-29: 495-505
  36. Shojania AM, Hornady G, Barnes PH (1968) Oral contraceptives and serum-folate level. Lancet 291: 1376-1377
  37. McLean FW, Heine MW, Held B, Streiff RR (1969) Relationship between oral contraceptive  and folic acid metabolism. Serum folateconcentrations. Am J ObstetGynecol 104: 745-747
  38. Castren OM, Rossi RR (1970) Effect of oral contraceptives on serum folic acid content. J ObstetGynaecol Br Commonw 77:548-550
  39. Briggs M (1975) Letter: Vitamin E status and oral contraceptives. Am J ClinNutr 28: 436
  40. Briggs M (1974) Letter:  Oral contraceptives and vitamin nutrition. Lancet 1:1234-1235
  41. Davis RE, Smith BK (1974) Pyridoxal, vitamin B12 and folate metabolism in women taking oral contraceptive agents. S Afr Med J 48: 1937-1940
  42. Lewis MC, King JC (1980) Effect of oral contraceptive agents on thiamin, riboflavin, and pantothenic acid status in young women. Am J ClinNutr 33:832-838
  43. Rose DP (1976) The influence of oestrogen on tryptophan metabolism in man ClinSci 31: 265-277
  44. Green TJ, Houghton LA, Donovan U, Gibson RS, O’Connor DL (1998) Oral contraceptives did not affect biochemical folate indexes and homocysteine concentrations in adolescent females. J Am Diet Assoc 98(1): 49-55
  45. Morris MS, Sakakeeny L, Jaques PF, Selhub J (2008) Plasma pyridoxal-5-phosphate in the US population: the National Health and Nutrition Examination Survey. 2003-2004. Am J ClinNutr 87:1446-1454
  46. McArthur JO, Tang H, Petoz P, Samman S (2013) Biological variability and impact of oral contraceptives on vitamins B6, B12 and Folate status in women of reproductive age. Nutrients 5: 3634-3645
  47. Lussana F, Zighetti ML, Bucciarelli P, Cugno M, Cattaneo M (2003) Blood levels of homocysteine, folate, vitamine B6 and B12 in women using oral contraceptives compared to non-users. Thromb Res 112: 37-41
  48. Møeller UK, Streym S, Heickendorff L, Mosekilde L, Reijnmark L (2012) Effects of 25OHD concentrations on changes of pregnancy and pregnancy outcomes: a cohort study in health Danish women. Eur J ClinNutr 66: 862-868
  49. Møeller UK, Streym S, Jensen JT, Mosekilde L, Schoenmakers I, Nigdikar S, Rejnmark L (2013) Increased plasma concentrations of vitamin D metabolites and vitamin D binding protein in women using hormonal contraceptives: a cross-sectional study. Nutr 5:3470-3480
  50. Villegas-Salas E, Ponce de León R, Juárez-Perez MA, Grubb GS (1997) Effect of vitamin B6 on the side effects of a low-dose combined oral contraceptive. Contraception 55(4): 245-8
  51. Bender DA, Wynick D (1981) Inhibition of kynureninase by estrogen sulphate: an alternative explanation for abnormal results of tryptophan load test in women receiving oestrogenic steroids. Br J Nurt 45: 259-265
  52. Braidman IP, Rose DP (1971)The effect of sex hormones on the activity of tryptophan oxygenase und other corticosteroid-inducible enzymes in rat liver. Biochem J 122:28P
  53. Rose 72??
  54. Price JM, Thornton MJ, Mueller LM (1967) Tryptophan metabolism in women using steroid hormones for ovulation control. Am J ClinNutr 20: 452-456
  55. Luhby AL, Brin M, Gordon M, Davis P, Murphy M, Spiegel H (1971) Vitamin B6 metabolism in users of oral contraceptive agents. I. Abnormal urinary xanthurenic acid exretion and its correction by pyridoxine. Am J ClinNutr 24: 684-693
  56. Aly HE, Donald EA, Simpson MHW (1971) Oral contraceptives and vitamin B6 metabolism. Am J ClinNutr 24: 297-303
  57. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J (2001) Low circulating vitamin B(6) is associated with elevation of the in?ammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 103:2788–2791
  58. Krintus M, Sypniewska G, Kuligowska-Prusinska M (2010) E?ect of second- and third-generation oral contraceptives on C-reactive protein, lipids and apolipoproteins in young, non-obese, non-smoking apparently healthy women. ClinBiochem 43:626–628
  59. Williams MJ, Williams SM, Milne BJ, Hancox RJ, Poulton R (2004) Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults.Int J ObestRelatMetabDisord28:998–1003
  60. Heseker H, Stahl A (2008) Vitamin B6. Ernährungs Umschau 2: 102-107
  61. Bielenberg J (2004) Wechselwirkungen zwischen oralen Kontrazeptiva und Vitaminen. Ärztezeitschrift für Naturheilverfahren 45, 12: 804-814
  62. Brown RR, Rose DP, Leklem JE, Linswiler H, Anand R (1975) Urinary 4-pyridoxic acid, plasma pyridoxal-5-phosphat and erythrocyte aminotransferase levels in oral contraceptive users receiving controlled intakes of vitamin B6. Am J ClinNutr 38: 10-19
  63. Deutsche Gesellschaft für Ernährung e.V. (DGE), Österreichische Gesellschaft für Ernährung (ÖGE), Schweizerische Gesellschaft für Ernährungsforschung (SGE), Schweizerische Vereinigung für Ernährung (SVE) (2013) Referenzwerte für die Nährstoffzufuhr. 1. Auflage, 5., korrigierter Nachdruck, Umschau, Braus, Frankfurt
  64. Deutsche Gesellschaft für Hämatologie und medizinische Onkologie e.V. (DGHO, Hrsg.) (2011) Eisenmangel und Eisenmangelanämie. Leitlinie. https://www.dgho-onkopedia.de/de/onkopedia/leitlinien/eisenmangel-und-eisenmangelanaemie/eisenmangel-und-eisenmangelana-mie.pdf (24.07.2014)
  65. Herzklotz R, Huber A (2010) Labordiagnose von Eisenstoffwechselstörungen. Schweiz Med Forum 10(30-31): 500-507

Der primäre Hyperparathyreoidismus eine unterschätze Erkrankung

Martin birkhaeuser, Peyman Hadji, Bruno Imthurn, alfred o. Mueck, Joseph Neulen, Christian Thaler, Inka Wiegratz, Ludwig Wildt

 

  1. Sowers MR, McConnell D, Jannausch M, Buyuktur AG, Hochberg M, Jamadar DA. (2006) Estradiol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum. 54: 2481–2487
  2. Christiansen C. (1993) Prevention and treatment of osteoporosis with hormone replacement therapy. Int J Fertil Menopausal Stud., 38 Suppl 1: 45–54
  3. Eisman J, Clapham S, Kehoe L; Australian BoneCare Study. (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res. 19: 1969–1975
  4. Clarkson TB, Meléndez GC, Appt SE. (2013) Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause. 20: 342–353
  5. Sadik R, Abrahamsson H, Stotzer PO. (2003) Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol. 38: 36–42
  6. Bossé R, DiPaolo T. (1996) The modulation of brain dopamine and GABAA receptors by estradiol: a clue for CNS changes occurring at menopause. Cell Mol Neurobiol. 16: 199–212
  7. Suzuki H, Barros RP, Sugiyama N, Krishnan V, Yaden BC, Kim HJ, Warner M, Gustafsson JÅ. (2013) Involvement of estrogen receptor ? in maintenance of serotonergic neurons of the dorsal raphe. Mol Psychiatry. 18: 674–680
  8. Bilezikian JP. (2012) Primary hyperparathyroidism. Endocr Pract. 18: 781-790
  9. Alex G, Morris L, Pasieka J, Perrier N. (2013) Nonclassical symptoms of primary hyperparathyroidism and their response to parathyroidectomy. Am Surg. 79: 337–343
  10. Ragno A, Pepe J, Badiali D, Minisola S, Romagnoli E, Severi C, D'Erasmo E. (2012) Chronic constipation in hypercalcemic patients with primary hyperparathyroidism. Eur Rev Med Pharmacol Sci. 16: 884–889
  11. Bai HX, Giefer M, Patel M, Orabi AI, Husain SZ. (2012) The association of primary hyperparathyroidism with pancreatitis. J Clin Gastroenterol. 46: 656–661
  12. Adami S, Marcocci C, Gatti D. (2002) Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res. 17 Suppl 2: N18–23
  13. Carrillo-López N, Román-García P, Rodríguez-Rebollar A, Fernández-Martín JL, Naves-Díaz M, Cannata-Andía JB. (2009) Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol. 20: 2009–2017
  14. Chiu KM, Arnaud CD, Ju J, Mayes D, Bacchetti P, Weitz S, Keller ET. (2000) Correlation of estradiol, parathyroid hormone, interleukin-6, and soluble interleukin-6 receptor during the normal menstrual cycle. Bone. 26: 79–85
  15. Hsu SC, Levine MA. (2002) Primary hyperparathyroidism in children and adolescents: the Johns Hopkins Children's Center experience 1984-2001. J Bone Miner Res. 17 Suppl 2: N44–50
  16. Giusti F, Tonelli F, Brandi ML. (2012) Primary hyperparathyroidism in multiple endocrine neoplasia type 1: when to perform surgery? Clinics (Sao Paulo). 67 Suppl 1: 141–144
  17. Pallan S, Rahman MO, Khan AA. (2012) Diagnosis and management of primary hyperparathyroidism. BMJ. 2012 Mar 19;344: e1013 
  18. Alex G, Morris L, Pasieka J, Perrier N. (2013) Nonclassical symptoms of primary hyperparathyroidism and their response to parathyroidectomy. Am Surg. 79: 337–343
  19. De Geronimo S, Romagnoli E, Diacinti D, D'Erasmo E, Minisola S. (2006) The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur J Endocrinol. 155: 415–420
  20. Osto E, Fallo F, Pelizzo MR, Maddalozzo A, Sorgato N, Corbetti F, Montisci R, Famoso G, Bellu R, Lüscher TF, Iliceto S, Tona F. (2012) Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation. 126: 1031–1039
  21. Macfarlane DP, Yu N, Donnan PT, Leese GP. (2011) Should 'mild primary hyperparathyroidism' be reclassified as 'insidious': is it time to reconsider? Clin Endocrinol (Oxf). 75: 730–737 
  22. Díaz-Soto G, Julián MT, Puig-Domingo M. (2012) Normocalcemic primary hyperparathyroidism: a newly emerging disease needing therapeutic intervention. Hormones (Athens). 11: 390–396

Paradigmenwechsel bei der Früherkennungsdiagnostik des Zervixkarzinoms?

Volker  Schneider

  1. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: Nutzenbewertung eines HPV-Tests im Primärscreening des Zervixkarzinoms. www.iqwig.de.
  2. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen: Nutzenbewertung eines HPV-Tests im Primärscreening des Zervixkarzinoms – Rapid Report. https://www.iqwig.de/de/projekte_ergebnisse/projekte/nichtmedikamentoese_verfahren/s13_03
  3. Robert-Koch-Institut: Krebs in Deutschland 2009/2010. Häufigkeiten und Trends. 9. Ausgabe  Berlin 2013
  4. Gustafsson L, Ponten J, Bergström R, Adami HO: International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer 1997; 71: 159-165
  5. globocan.iarc.fr/pages/fact_sheets__population.aspx (Zugriff Aug 24, 2014)
  6. Marquardt K, Büttner HH, Broschewitz U, Barten M, Schneider V: Persistent carcinoma in cervical cancer screening: Non-participation is the most significant cause. Acta Cytol 2011; 55: 433-437.
  7. Bos AB, Rebolj M, Habbema JD, van Ballegooijen M: Non-attendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands. Int J Cancer 2006, 119: 2372-5
  8. Andrae  B, Kemetli L, Sparén P, et al. Screening-preventable cervical cancer risks: Evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008; 100: 622-629.
  9. Spayne J, Ackerman I, Milosevic M et al. Invasive cervical cancer: a failure of screening. Europ J Public Health 2008; 18: 162-165 
  10. Kassenärztliche Bundesvereinigung: Vereinbarung von Qualitätssicherungs-maßnahmen nach § 135 Abs. 2 SGB V zur zytologischen Untersuchung von Abstrichen der Cervix uteri (Qualitätssicherungsvereinbarung Zervix-Zytologie) Deutsches Ärzteblatt 2007, 104, 7. September: C2094 - C2099
  11. European Commission: EU guidelines for quality assurance in cervical screening – 2nd edition: Luxembourg: Office for Official Publications of the European Communities; European Communities, Luxembourg, 2008. 
  12. Anttila A, Ronco G and 65 collaborators: Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009; 45: 2685-2708.
  13. Arbyn, M, Rebolj M, DeKok IM, et al. The challenges of organizing cervical screening programs in the 15 old member states of the European Union. Eur J Cancer 2009; 45: 2671-2678.
  14. Anttila A, von Karsa L, Aasmaa A, Fender M, Patrick J, Rebolj M, Nicula F, et al: Cervical cancer screening policies and coverage in Europe. Eur J Cancer 2009; 45: 2649-2658
  15. European Commission: Cancer screening in the European Union. Report on the implementation of the Council Recommendation of 2 December 2003 on Cancer Screening COM (2008) 882.
  16. europa.eu/eu-law/decision-making/legal-acts/index_en.htm (Zugriff 24. Aug. 2014)
  17. europa.eu/legislation_summaries/public_health/index_en.htm (Zugriff 24. Aug., 2014)
  18. Kerek-Bodden H, Altenhofen L, Brenner G, Franke A. Durchführung einer versichertenbezogenen Untersuchung zur Inanspruchnahme der Früherkennung auf Zervixkarzinom in den Jahren 2002, 2003 und 2004 auf der Basis von Abrechnungs-daten: Abschlussbericht 05.2009. URL: www.zi-berlin.de/k_frueh_prog/ downloads/Abschlussbericht_090716.pdf
  19. Leuchs A, König J, Blettner M, Ressing M, Klug S: Auswertung der Nichtteilnehmerinnen-Nachfassbögen der Basisuntersuchung der MARZY-Kohorte. Gmds 2009 DOI: 10.3205/09gmds011
  20. Mund M: Wird mit dem neuen Gesetz alles besser ?  Dtsch Aerztebl 2012, 109, A 2513-4.
  21. Gemeinsamer Bundesausschuss. Tragende Gründe zum Beschluss zu den Krebsfrüherkennungsrichtlinien: Methoden zur Früherkennung des Zervixkarzinoms. 19.12.2006. URL: g-ba.de/downloads/40-268-107/2006-12-19_-KFU-HPV-Zervix_TGr.pdf
  22. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJLM: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials Lancet 2014 383: 524-532.
  23. Freitag U: Nutzen des HPV-Tests im Primärscreening des Zervixkarzinoms erneut nicht belegbar. Frauenarzt 2014; 55:649-650.
  24. Vesco KK, Whitlock EP, Eder M, Lin J, Burda BU, Senger CA, Holmes RS, Fu R, Zuber S. Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 86. AHRQ Publication No. 11-05156-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; May 2011
  25. Austin RM, Zhao C: Is 58 % sensitivity for detection of cervical intraepithelial neoplasia 3 and invasive cervical cancer optimal for cervical screening ? Cytojournal 14: 11: 14 
  26. Dudding N: Sensitivity and specificity of HPV testing: what are the facts ? Cytopathology 2013; 24: 283-288.
  27. Farnsworth A: Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: An Australian perspective.  Acta  Cytol 2011; 55: 307-312.
  28. Rebolj M, Preisler S, Moller Ejegod D, Rygaard C, Lynge E, Bonde J: Disagreement between human papillomavirus assays: An unexpected challenge for the choice of an assay in primary cervical screening. PLoS One 2014 9: e86835
  29. Canadian Task Force on Preventive Health Care: Recommendations on screening for cervical cancer. CMAJ 2013; 185(1): 35-45
  30. Marquardt K, Kolankowska I, Pfandzelter R: Jahresstatistik Zervixzytologie. Frauenarzt 2014; 55: 732-733.